South Korean company nabs plant that makes generic Botox

Pharma Research Products has obtained control of this BioCND plant in South Korean that manufacturers generic injectable botulinum toxin. (PRP)

PharmaResearch Products, a South Korean company focused on “regenerative” and cosmetic medicines has picked up a plant that manufactures generic injectable botulinum toxin, the same ingredient used in the popular wrinkle remover Botox.

Seongnam-si, Gyeonggi-do- based PRP said in a press release, that it had invested about $35 million to “secure" majority ownership of the botulinum toxin type A injection (ReNtox) production facility of BioCND, a South Korean Biotech that is developing biosimilars. 

The newly built, 6,000-square-meter plant, is in Gangneung-si on the East Coast of South Korea. PRP says it has an initial capacity of 2 million vials of the ReNtox per year. The BioCND plant was completed last summer, The South Korea Herald reported, and the biotech had obtained more than $870,000 in private investments to operate it. No reason was given by BioCND, which is working on several other biosimilar products, for selling control of the facility.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The plant, which has 50 employees, is not currently producing on a commercial scale, PRP said but an application for a botulinum injection biosimilar is under evaluation by South Korea's Ministry of Food and Drug Safety (MFDS), the company said in an email. A GMP inspection of the plant is expected in the second half of this year.

PRP said the acquisition of the plant completes its “proprietary line of facial esthetic products.” It already has a line of hyaluronic acid fillers and Rejuran, a micro injection filler.

RELATED: Look out, Allergan: Doctor surveys show the 'Botox competitive threat is real'

While the facility was built to meet MFDS GMP requirements, PRP said it has designs on the “worldwide facial esthetic market.” But in wider market, PRP will face competition. There are other companies currently working on biosimilars of Allergan’s big-selling Botox for the U.S. market.

PRP also has a plant under construction, slated to be complete this year, for production of some of its other products. 

Suggested Articles

Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.

Despite pricing pressure from domestic rivals, Keytruda could still generate billions of dollars a year in China, Cantor analysts predict

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.